IL303444A - Dsg2 compositions and methods for the treatment of covid-19 - Google Patents

Dsg2 compositions and methods for the treatment of covid-19

Info

Publication number
IL303444A
IL303444A IL303444A IL30344423A IL303444A IL 303444 A IL303444 A IL 303444A IL 303444 A IL303444 A IL 303444A IL 30344423 A IL30344423 A IL 30344423A IL 303444 A IL303444 A IL 303444A
Authority
IL
Israel
Prior art keywords
dsg2
isolated polypeptide
covid
protein
domain
Prior art date
Application number
IL303444A
Other languages
English (en)
Hebrew (he)
Original Assignee
Arvada Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvada Therapeutics Inc filed Critical Arvada Therapeutics Inc
Publication of IL303444A publication Critical patent/IL303444A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL303444A 2020-12-15 2021-12-15 Dsg2 compositions and methods for the treatment of covid-19 IL303444A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063125583P 2020-12-15 2020-12-15
US202163274715P 2021-11-02 2021-11-02
PCT/US2021/063433 WO2022132854A1 (en) 2020-12-15 2021-12-15 Dsg2 compositions and methods for the treatment of covid-19

Publications (1)

Publication Number Publication Date
IL303444A true IL303444A (en) 2023-08-01

Family

ID=79425717

Family Applications (1)

Application Number Title Priority Date Filing Date
IL303444A IL303444A (en) 2020-12-15 2021-12-15 Dsg2 compositions and methods for the treatment of covid-19

Country Status (9)

Country Link
EP (1) EP4263588A1 (https=)
JP (1) JP2024500250A (https=)
KR (1) KR20230120141A (https=)
AU (1) AU2021400845A1 (https=)
CA (1) CA3202364A1 (https=)
IL (1) IL303444A (https=)
MX (1) MX2023006704A (https=)
TW (1) TW202237634A (https=)
WO (1) WO2022132854A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024005327A (es) * 2021-11-02 2024-05-21 Arvada Therapeutics Inc Composiciones y metodos de dsg2.
CN116458893A (zh) * 2023-04-19 2023-07-21 电子科技大学 一种covid-19后心肌缺血的早期筛查方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100316347B1 (ko) 1998-09-15 2002-08-27 한미약품(주) 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법
DE10057397A1 (de) 2000-11-18 2002-05-23 Hella Kg Hueck & Co Vorrichtung zur Ölstandsmessung
US20100303723A1 (en) * 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
US20190353652A1 (en) * 2017-01-13 2019-11-21 The Hospital For Sick Children Method for Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy

Also Published As

Publication number Publication date
MX2023006704A (es) 2023-06-20
WO2022132854A1 (en) 2022-06-23
JP2024500250A (ja) 2024-01-05
KR20230120141A (ko) 2023-08-16
AU2021400845A1 (en) 2023-07-13
CA3202364A1 (en) 2022-06-23
TW202237634A (zh) 2022-10-01
EP4263588A1 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
ES2426352T3 (es) Uso de la endoglucosidasa EndoS para el tratamiento de enfermedades mediadas por la inmunoglobulina G
US20180112193A1 (en) Csf1 therapeutics
CN107921085B (zh) 用于治疗衰老相关病症的方法和组合物
EA009938B1 (ru) ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ С ПРИМЕНЕНИЕМ ИНТЕРФЕРОНА-β
CN106573072A (zh) 降低血清胆固醇的方法
IL303444A (en) Dsg2 compositions and methods for the treatment of covid-19
CN111423502A (zh) 多肽、其衍生物及其在制备抗肺纤维化的药物中的应用
US10034915B2 (en) Small heat shock proteins and active fragments thereof as a therapy for inflammation and ischemia
US20240043495A1 (en) Dsg2 compositions and methods for the treatment of covid-19
JP6181158B2 (ja) TNF−α阻害剤としてのTACEプロドメインの変異体およびその医学的使用
JP6087429B2 (ja) 変形されたヒト腫瘍壊死因子受容体−1ポリペプチドの新規用途
CA2891386A1 (en) Compositions and methods for the treatment of ectodermal dysplasia
US20240279304A1 (en) Dsg2 compositions and methods
CN114409733A (zh) 靶向抑制mlkl乙酰化的多肽和/或其衍生物及其用途
CN116648255A (zh) 用于治疗covid-19的dsg2组合物和方法
CN108210886B (zh) Metrnl在防治溃疡性结肠炎中的应用
US20190358307A1 (en) Therapeutic agent for cerebral infarction
US20250276047A1 (en) Methods of treating diseases associated with traumatic brain injury
KR20070059009A (ko) 뮤신3 egf-유사 도메인
WO2022020544A1 (en) Method of treating an inflammatory condition
GB2241891A (en) Tumour necrosis factor compositions for treating inflammatory disease
KR20240138585A (ko) Nampt 유래 펩타이드를 유효성분으로 포함하는 염증성 장 질환 개선, 예방 또는 치료용 조성물
CN119874872A (zh) 一种mita铰链区突变多肽及其在自身免疫性疾病中的应用
CN113144174A (zh) 治疗高尿酸相关性疾病的药物
HK1223556B (zh) Il-22二聚体在制备用於治疗胰腺炎的药物中的用途